Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1126/science.abh1766 http://scihub22266oqcxt.onion/10.1126/science.abh1766 34210892!9269068!34210892     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Science 2021 ; 373 (6556): ä Nephropedia Template TP {{tp|p=34210892|t=2021. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants |pdf=|usr=}}{{34210892}} gab.com Text Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants JO: Science http://www.kidney.de/pget.php?&tw=1&pmid=34210892 #FOAvip The emergence of highly transmissible SARS-CoV-2 variants of concern (VOCs) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identified four receptor binding domain-targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants, including the B.1.1.7, B.1.351, P.1, B.1.429, B.1.526, and B.1.617 VOCs. Two antibodies are ultrapotent, with subnanomolar neutralization titers [half-maximal inhibitory concentration (IC(50)) 0.3 to 11.1 nanograms per milliliter; IC(80) 1.5 to 34.5 nanograms per milliliter). We define the structural and functional determinants of binding for all four VOC-targeting antibodies and show that combinations of two antibodies decrease the in vitro generation of escape mutants, suggesting their potential in mitigating resistance development. Twit Text FOAVip Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants ????Science http://www.kidney.de/pget.php?&tw=1&pmid=34210892 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34210892 #FOAvip English Wikipedia <ref>{{Cite pmid|34210892}}</ref> Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants #MMPMID34210892 Wang L; Zhou T; Zhang Y; Yang ES; Schramm CA; Shi W; Pegu A; Oloniniyi OK; Henry AR; Darko S; Narpala SR; Hatcher C; Martinez DR; Tsybovsky Y; Phung E; Abiona OM; Antia A; Cale EM; Chang LA; Choe M; Corbett KS; Davis RL; DiPiazza AT; Gordon IJ; Hait SH; Hermanus T; Kgagudi P; Laboune F; Leung K; Liu T; Mason RD; Nazzari AF; Novik L; O'Connell S; O'Dell S; Olia AS; Schmidt SD; Stephens T; Stringham CD; Talana CA; Teng IT; Wagner DA; Widge AT; Zhang B; Roederer M; Ledgerwood JE; Ruckwardt TJ; Gaudinski MR; Moore PL; Doria-Rose NA; Baric RS; Graham BS; McDermott AB; Douek DC; Kwong PD; Mascola JR; Sullivan NJ; Misasi J Science 2021[Aug]; 373 (6556): ä PMID34210892show ga The emergence of highly transmissible SARS-CoV-2 variants of concern (VOCs) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identified four receptor binding domain-targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants, including the B.1.1.7, B.1.351, P.1, B.1.429, B.1.526, and B.1.617 VOCs. Two antibodies are ultrapotent, with subnanomolar neutralization titers [half-maximal inhibitory concentration (IC(50)) 0.3 to 11.1 nanograms per milliliter; IC(80) 1.5 to 34.5 nanograms per milliliter). We define the structural and functional determinants of binding for all four VOC-targeting antibodies and show that combinations of two antibodies decrease the in vitro generation of escape mutants, suggesting their potential in mitigating resistance development. |Angiotensin-Converting Enzyme 2/antagonists & inhibitors/metabolism[MESH] |Antibodies, Neutralizing/chemistry/*immunology/metabolism[MESH] |Antibodies, Viral/chemistry/*immunology/metabolism[MESH] |Antibody Affinity[MESH] |Antigen-Antibody Reactions[MESH] |COVID-19/*immunology/virology[MESH] |Humans[MESH] |Immune Evasion[MESH] |Immunoglobulin Fab Fragments/immunology/metabolism[MESH] |Mutation[MESH] |Neutralization Tests[MESH] |Protein Domains[MESH] |Receptors, Coronavirus/antagonists & inhibitors/metabolism[MESH] |SARS-CoV-2/genetics/*immunology/*pathogenicity[MESH]Ultrapotent antibodies against diverse and highly transmissible SARS-C(epmc).pdf DeepDyve Pubget Overpricing